25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)
(2021) ESMO Congress 2022 — Location: (France) Paris (9.September.2022)
Files
2022_Riudavets_ESMO2022.pdf
Open Access - Adobe PDF
- 89.35 KB
Details
- Authors
- Abstract
- BACKGROUND : The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) >3 and lactate dehydrogenase (LDH) >upper limit of normal (ULN), is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small cell lung cancer (NSCLC). We aimed to assess if baseline LIPI correlates with durvalumab efficacy after chemoradiotherapy (ChRT) in the locally advanced setting. [...]
- Affiliations
Citations
Riudavets Melia, M., Auclin, E., Aboubakar Nana, F., Ponce Aix, S., Dal Maso, A., Bluthgen, V., Mielgo, X., Mussat, E., Reyes, R., Benítez, J., Lupinacci, L., Duchemann, B., de Giglio, A., Bautista, J., Audigier-Valette, C., Scheffler, M., Campayo, M., Besse, B., Planchard, D., & Mezquita, L. (2021). 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC). Annals of Oncology, 32(Suppl 7), S1384. https://doi.org/10.1016/j.annonc.2021.10.041 (Original work published 2021)